Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer

Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge 

Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy

Results from TAILORx trial presented at ESMO 2019

PROs encourage patient-centred cancer care

Results from the MONARCH 2 and MONALEESA-3 trials

Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials

Results from the PROMISE-meso trial presented

Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer

Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers